Song Woo-Jung, Chang Yoon-Seok
Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea.
Asia Pac Allergy. 2012 Jan;2(1):76-85. doi: 10.5415/apallergy.2012.2.1.76. Epub 2012 Jan 31.
Magnesium sulfate (MgSO(4)) has been considered as an adjunct therapy for severe and life-threatening asthma exacerbation. The literature search was performed using MEDLINE, EMBASE, Cochrane Library and Google Scholar to summarize the current state of knowledge regarding magnesium therapy in acute exacerbation of adult asthma. A total of 16 trials and 4 meta-analyses were identified. As results, intravenous MgSO(4) was beneficial in severe exacerbation, but evidence for nebulized magnesium was insufficient. However, larger trials are required to draw confirmative conclusions on the efficacy. Regarding the safety concern, the risk of major toxicity appears to be very low at usual doses described in the literature. Additionally, results from 4 surveys were examined on the gaps between knowledge and practice, and on the barrier to the use of MgSO(4) at emergency departments. This literature review summarized the up-to-date evidence on the issues regarding the use of MgSO(4) for acute asthma. We expect more studies to be conducted for evidence making in the Asian-Pacific regions.
硫酸镁(MgSO₄)已被视为重度及危及生命的哮喘急性发作的辅助治疗方法。通过检索MEDLINE、EMBASE、Cochrane图书馆和谷歌学术来总结目前关于成人哮喘急性发作时镁治疗的知识现状。共识别出16项试验和4项荟萃分析。结果显示,静脉注射硫酸镁对重度急性发作有益,但雾化镁的证据不足。然而,需要更大规模的试验才能就其疗效得出确定性结论。关于安全性问题,在文献中描述的常用剂量下,主要毒性风险似乎非常低。此外,还审查了4项关于知识与实践差距以及急诊科使用硫酸镁的障碍的调查结果。这篇文献综述总结了关于使用硫酸镁治疗急性哮喘问题的最新证据。我们期望在亚太地区开展更多研究以提供证据。